<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>While surgery is the cornerstone treatment for early-stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, chemotherapy is the first treatment option for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> when <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lesions are frequently not fully resectable at presentation </plain></SENT>
<SENT sid="1" pm="."><plain>Mortality from <z:hpo ids='HP_0003003'>colon cancer</z:hpo> has decreased over the past 30 years, but there is still a huge <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in survival rates that can be mainly explained by patient and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> characteristics, host response factors, and treatment modalities </plain></SENT>
<SENT sid="2" pm="."><plain>The management of unresectable <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> is a global treatment strategy, which applies several lines of therapy, salvage surgery, maintenance, and treatment-free intervals </plain></SENT>
<SENT sid="3" pm="."><plain>The individualization of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment is based on the evaluation of prognostic factors for survival (serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase level, performance status), and predictive factors for treatment efficacy [Kirsten rat <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog (KRAS) mutation status] </plain></SENT>
<SENT sid="4" pm="."><plain>The available treatment modalities for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> are chemotherapy (fluoropyrimidine, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, irinotecan), anti-angiogenic agents (e.g. bevacizumab), and anti-epidermal growth factor agents (cetuximab, panitumumab) </plain></SENT>
<SENT sid="5" pm="."><plain>The increasing number of active compounds dictates the strategy of trials evaluating these treatments either in combination or sequentially </plain></SENT>
<SENT sid="6" pm="."><plain>Alternative outcomes that can be measured earlier than overall survival are needed to shorten the duration and reduce the size and cost of clinical trials </plain></SENT>
</text></document>